ScholarLens Back to search
2019•Kidney International ReportsOpen access

SUN-059 Significance of fibroblast growth factor-23 (FGF23) level in hemodialysis patients

M. Tashiro, Hideaki Shima, T. Inoue, Kimiko Kawahara, K Miya, Kunihiro Okada, Jun Minakuchi, S Kawashima

Open full text 0 citations

Abstract

Fibroblast growth factor-23 (FGF23) is a phosphaturic hormone, and its levels increases as kidney function declines. Increased levels of FGF23 occur primarily as a result of a net positive phosphate balance leading to increased renal phosphate excretion. Although FGF23 helps to prevent hyperphosphatemia, elevated circulating levels are independently associated with vascular dysfunction, left ventricular hypertrophy, and increased risk for death in patients with CKD.

Open-access reader

About this research paper

What this paper is about

Fibroblast growth factor-23 (FGF23) is a phosphaturic hormone, and its levels increases as kidney function declines. Increased levels of FGF23 occur primarily as a result of a net positive phosphate balance leading to increased renal phosphate excretion. Although FGF23 helps to prevent hyperphosphatemia, elevated circulating levels are independently associated with vascular dysfunction, left ventricular hypertrophy, and increased risk for death in patients with CKD.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Fibroblast growth factor-23 (FGF23) is a phosphaturic hormone, and its levels increases as kidney function declines. Increased levels of FGF23 occur primarily as a result of a net positive phosphate balance leading to increased renal phosphate excretion. Although FGF23 helps to prevent hyperphosphatemia, elevated circulating levels are independently associated with vascular dysfunction, left ventricular hypertrophy, and increased risk for death in patients with CKD.

Key concepts: Fibroblast growth factor 23, Hyperphosphatemia, Medicine, Internal medicine, Endocrinology, Hemodialysis, Renal function, Left ventricular hypertrophy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
SUN-059 Significance of fibroblast growth factor-23 (FGF23) level in hemodialysis patients — Research Paper | ScholarLens